This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwartsmann, G. Articles by Di Leone, L. Search for Related Content PubMed PubMed Citation Articles by Schwartsmann, G. Articles by Di Leone, L. Social Bookmarking                            What's this?

Anticancer Drug Discovery and Development Throughout the World

From the South-American Office for Anticancer Drug Development, Lutheran University of Brazil, and Postgraduate Course in Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, and Cancer Research Center, University of Chicago, Chicago, IL; Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD; Department of Hematology/Oncology, University of Singapore, Singapore; Division of Medical Oncology, National Cancer Center Hospital, and Pharmaceuticals and Medical Devices Evaluation Center, National Institute of Health Sciences, Ministry of Health, Labor, and Welfare, Tokyo, Japan; Clinical Research, Translational Development, Novartis Oncology, East Hanover, NJ; and Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD.

Address reprint requests to Gilberto Schwartsmann, MD, PhD, Comprehensive Cancer Center (CINCAN), Lutheran University of Brazil (ULBRA), Campus Central da ULBRA, Predio 22-5 Andar Canoas, Brazil; email: gschwart.ez{at}terra.com.br

ABSTRACT: This year’s American Society of Clinical Oncology International Symposium devoted 2 hours to a lively discussion of various aspects of anticancer drug discovery and development throughout the world. The scientific program started with an overview of efforts directed toward promoting international collaboration in natural product–derived anticancer drug discovery. This was followed by a discussion on the importance of interethnic differences and pharmacogenetics in anticancer drug development. Thereafter, this part of the program was completed by a description of the activities of the newly created Singapore-Hong Kong-Australia Drug Development Consortium and an overview of the contribution of Japan to anticancer drug development. The logistics and regulatory aspects of clinical trials with new anticancer agents in different parts of the world were then presented, with an emphasis on Europe, North America, and Japan. The program was completed with a panel discussion of the efforts to harmonize the exchange of clinical data originating from one region of the globe with other territories, with input from official representatives of the United States Food and Drug Administration and the Medical Devices Evaluation Center of Japan.

This report is a summary of the American Society of Clinical Oncology International Symposium held on May 19, 2002, during the Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002.

M.J.R. is a coinventor on two issued patents related to irinotecan and has significant financial relationships with several companies that have a major interest in topics mentioned in this article. These companies include Variagenics, a pharmacogenomics company focused on oncology (chair of Scientific Advisory Board), Xanthus Life Sciences, a company developing amonafide (consultant), and Datatrak International, a company providing global electronic data capture services (director).

© 2002 by American Society of Clinical Oncology.

0732-183X/02/2018s/$20.00

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. U. Ty, S. J. See, J. P. Rao, J.B.K. Khoo, and M. C. Wong Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: A Singapore experience Neurology, January 24, 2006; 66(2): 247 - 249. [Abstract] [Full Text] [PDF]